Health Care · Pharmaceutical Preparations

BNTC Benitec Biopharma Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 180889865 filings
Russell 2000

BNTC at a glance

Benitec Biopharma Inc. (BNTC, SEC CIK 1808898) filed its latest 10-K annual report on September 14, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as June 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended June 30, 2024 (FY2024), Benitec Biopharma Inc. (BNTC) reported revenue of $0. Diluted EPS was -$5.51.
  • As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Benitec Biopharma Inc. (BNTC) shares worth $73.3 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by SUVRETTA CAPITAL MANAGEMENT, LLC on December 29, 2025 of 11,587 shares at $13.44 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2024
$0
10-K XBRL
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
23 funds
$73.3M · +0 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 2.02 · Item 5.03

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Jun 30, 2026

Full analysis →

Risk Factors

  • Legislative risk: Medicare drug-price negotiation under Inflation Reduction Act of 2022 may limit pricing on reimbursed products
  • Geopolitical risk: U.S. federal government workforce reductions cause FDA staffing shortages, potentially delaying product review and approvals
  • Operational risk: Dependency on AAV delivery vectors may trigger immune responses restricting patient eligibility and efficacy of gene therapies
  • Market disruption risk: Competition from antisense RNA therapies with more advanced development than ddRNAi-based products
  • Financial risk: Accumulated losses $273.7M with cash runway estimated only for 12 months, requiring uncertain future capital raises

Business Overview

  • Core business: Clinical-stage biotech developing permanent gene silencing and replacement therapies using proprietary ddRNAi platform
  • New product focus: BB-301, first silence and replace AAV-based gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD) in Phase 1b/2a clinical trial since Nov 2023
  • Strategic emphasis on single-administration, durable gene therapy addressing limitations of RNAi, targeting rare disease with $1B+ commercial potential
  • Employee count 24 as of June 30, 2026, with 17 R&D staff, reflecting small, specialized workforce
  • Noteworthy patent advances include 2 new patent families in 2025-2026 covering interoperative delivery devices and modified AAV vectors for BB-301

Management Discussion & Analysis

  • Revenue $0 for FY2026 and FY2025, no product sales generated
  • Operating expenses $51.2M FY2026 vs $41.8M FY2025; R&D $23.4M vs $18.3M and G&A $27.8M vs $23.4M
  • Best segment: none with revenue; highest expense: G&A $27.8M vs R&D $23.4M in FY2026
  • Cash $180M as of June 30, 2026; net cash from financing $99.0M mostly from $104.5M stock issuance less $6.3M costs; operating cash outflow $16.5M
  • Management outlook: increased R&D and G&A expenses expected; cash sufficiency projected for 12+ months; risks include development uncertainties and financing needs

AI summary of the BNTC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to previously disclosed risk factors in the fiscal 2026 Form 10-K
  • Significant carried-forward risks not detailed in this 10-Q section

Management Discussion & Analysis

  • Revenue $0, no product sales; no YoY revenue comparison disclosed
  • Operating expenses $14.5M vs $9.8M YoY, R&D $8.6M vs $3.4M
  • R&D highest growth area, up from $3.4M to $8.6M; G&A $5.9M vs $6.4M
  • Cash $176M; operating cash use $3.6M vs $3.4M YoY
  • Continued losses expected; cash sufficient for at least twelve months, with clinical-development funding risks

AI summary of the BNTC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal-quarter results for period ended September 30, 2026 announced
  • Operational update accompanies financial results

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Fiscal year-end shifted from June 30 to December 31, effective November 12, 2026
  • Six-month transition period, July 1 through December 31, 2026, reported in a Transition Form 10-K

Item EX-99.1: Item EX-99.1

  • BB-301 interim data showed a 100% responder rate across six Cohort 1 and three Cohort 2 patients, with no serious adverse events reported
  • Pivotal BB-301 study design targeted for Q1 2027, with trial initiation still planned for mid-2027
Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Interim Phase 1b/2a data support BB-301 efficacy, with 100% response across six low-dose and three high-dose patients
  • High dose outperformed low dose at Month 3 for throat emptying, 100% vs 67%, and swallowing capacity, 67% vs 17%

Item 7.01: Regulation FD Disclosure

  • Positive interim Phase 1b/2a results for high-dose BB-301, a potential clinical validation milestone
  • Continued durable improvements for low-dose BB-301, supporting ongoing therapeutic activity
Filed Oct 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • FDA requested additional OPMD Natural History Study data before confirming BB-301 pivotal design, creating modest regulatory execution risk
  • Final pivotal study design targeted for 1Q 2027, with patient enrollment still planned for mid-2027

Item 7.01: Regulation FD Disclosure

  • Benitec received formal FDA feedback following a Type C meeting held in Q3 2026
  • October 5, 2026 press release provides the company’s regulatory update

AI summaries of BNTC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BNTC

Don't miss the next BNTC filing

  • Alerts as it files. A push when BNTC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BNTC, by share count.
  • Ask anything. An AI agent that reads every BNTC filing and answers with sources.

BNTC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
BUCHI J KEVINGJun 29, 2026-
Friedman David MatthewAMay 26, 2026-
Mates SharonAJan 22, 2026-
SUVRETTA CAPITAL MANAGEMENT, LLCBuyDec 29, 2025$13.44
SUVRETTA CAPITAL MANAGEMENT, LLCBuyDec 29, 2025$13.44
SUVRETTA CAPITAL MANAGEMENT, LLCBuyDec 26, 2025$13.10
SUVRETTA CAPITAL MANAGEMENT, LLCBuyDec 26, 2025$13.10
SUVRETTA CAPITAL MANAGEMENT, LLCBuyDec 23, 2025$12.85

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue$0--
Operating Income-$22.5M-$41.8M-$51.2M
Net Income--$37.9M-$45.5M
Balance Sheet
Total Assets$52.2M$99.6M$182.6M
Equity-$97.3M$177.0M
ROE--39.0%-25.7%
Per Share
EPS$-5.51$-1.05$-0.98
Cash Flow
Operating CF-$19.4M-$23.6M-$16.5M
CapEx$179K$18K$105K

Source: XBRL data in Benitec Biopharma Inc. (BNTC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BNTC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BNTC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202623$73.3M
Q2 202623$97.0M
Q1 202620$70.9M
Q4 202517$50.5M
Q3 202515$74.4M
Q2 202514$57.3M
Q1 20259$44.2M
Q4 20245$42.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 126 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BNTC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 13, 2026Analysis-
10-QNov 13, 2026Analysis
8-KOct 28, 2026Analysis-
8-KOct 5, 2026Analysis-
8-KSep 30, 2026Analysis-
8-KSep 24, 2026Analysis-
10-KSep 14, 2026Analysis
8-KSep 14, 2026Analysis-
4Jun 30, 2026--
8-KMay 29, 2026Analysis
4May 28, 2026-
8-KMay 14, 2026Analysis
10-QMay 14, 2026Analysis
10-QFeb 12, 2026Analysis
8-KFeb 12, 2026-
4Jan 26, 2026-
4Dec 29, 2025-
4Dec 22, 2025-
4Dec 3, 2025-
4Dec 3, 2025-
4Dec 3, 2025-
SC 13GDec 3, 2025-
4Dec 3, 2025-
4Dec 3, 2025-
8-KDec 2, 2025-

Related Health Care companies

All Health Care →

BNTC SEC filings: frequently asked questions

Which institutions hold BNTC stock?

As of September 30, 2026, the largest Benitec Biopharma Inc. (BNTC) holders among the 13F filers tracked by SignalX were Franklin Resources ($22.4 million), BlackRock ($14.3 million), Vanguard Capital Management LLC ($10.4 million), Millennium Management ($7.6 million), State Street Corp ($4.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BNTC's revenue in fiscal year 2024?

For the fiscal year ended June 30, 2024 (FY2024), Benitec Biopharma Inc. (BNTC) reported revenue of $0. Diluted EPS was -$5.51. The figures come from the XBRL data in the 10-K.

What are the main risks in BNTC's latest 10-K?

In the 10-K filed September 14, 2026, Benitec Biopharma Inc. (BNTC) flagged: Legislative risk: Medicare drug-price negotiation under Inflation Reduction Act of 2022 may limit pricing on reimbursed products. Geopolitical risk: U.S. federal government workforce reductions cause FDA staffing shortages, potentially delaying product review and approvals. (AI summary of the Risk Factors section.)

What did BNTC report in its latest 8-K?

Benitec Biopharma Inc. (BNTC) filed an 8-K on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Fiscal-quarter results for period ended September 30, 2026 announced.

What are the latest BNTC SEC filings?

Benitec Biopharma Inc. (BNTC) filed its latest 10-K annual report on September 14, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on June 30, 2026.

What is BNTC's SEC CIK number?

Benitec Biopharma Inc. (BNTC)'s SEC Central Index Key (CIK) is 1808898. EDGAR lists every BNTC filing under that number.

Ask anything about BNTC

The research agent reads BNTC's filings, financials, insider trades and 13F holders, then answers with sources.